Daiichi Sankyo
Daiichi Sankyo's Enhertu Benefits HER2-Positive Colorectal Cancer Patients, ASCO Data Show
The data from the Phase II trial will help Daiichi Sankyo further refine the drug's dose and eligible population in colorectal cancer.
NICE Recommends Enhertu for Advanced HER2-Positive Breast Cancer Through Cancer Drugs Fund
While more data are collected, Daiichi Sankyo and AstraZeneca's trastuzumab deruxtecan is available to pretreated, HER2-positive breast cancer patients in the UK.
Daiichi Sankyo Begins Phase I/II Trial of Menin Inhibitor in AML
The trial is evaluating DS-1594 alone and with other drugs in AML and ALL patients who have a MLL rearrangement or NPM1 mutation.
Daiichi Sankyo, AstraZeneca Begin Phase II Study of Enhertu in Colorectal Cancer
The trial is evaluating Enhertu at two doses in metastatic colorectal cancer patients whose tumors overexpress HER2.
Daiichi Sankyo, AstraZeneca Begin Phase II Study of Enhertu in HER2-Mutated NSCLC
The study will evaluate the drug's activity at two different doses for patients with previously treated HER2-positive NSCLC.